VARS1 (valyl-tRNA synthetase 1) catalyzes the aminoacylation of valine to its cognate tRNA, a critical step in protein translation occurring in the cytosol 1. The enzyme contains catalytic and aminoacylation domains essential for ligand recognition, substrate specificity, and tRNA interaction 1. Biallelic VARS1 variants cause autosomal recessive neurodevelopmental disorder characterized by progressive microcephaly, seizures, intellectual disability, and cortical atrophy 1. Disease-causing variants include truncating mutations causing loss-of-function and missense variants in catalytic domains that disrupt protein dynamics and RNA-interaction surfaces 1. Additionally, VARS1 variants have been associated with fetal akinesia deformation sequence and placental pathology 2. Beyond its housekeeping translation function, VARS1 exhibits disease-specific roles in cancer biology. VARS1 is overexpressed in aggressive hepatocellular carcinoma and promotes tumor aggressiveness through MAGI1 downregulation 3. In melanoma, VARS1 serves as a hub gene in M2-like tumor-associated macrophage modules, promoting cancer cell migration/invasion and M2 macrophage polarization while suppressing CD8 T cell infiltration and immunotherapy response 4. VARS1 also represents a potential therapeutic target in ankylosing spondylitis 5 and was identified as a papillary thyroid carcinoma risk-associated gene 6.